PDIA4 promotes glioblastoma progression via the PI3K/AKT/m-TOR pathway. 2022

Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, PR China; Sichuan Clinical Medical Research Center for Neurosurgery, Luzhou, 646000, PR China.

Protein disulfide isomerase A4 (PDIA4) is highly expressed in clear cell ovarian carcinoma and lung cancer. Through analysis of TCGA database and CGGA database, we noted that PDIA4 is a key promotor of glioblastoma (GBM). However, the detailed role and molecular mechanism of PDIA4 in GBM remain unclear. In this study, the expression pattern and biological role of PDIA4 in GBM was investigated. PDIA4 was overexpressed in GBM tumor samples and cell lines and positively correlated with pathological grades in glioma patients. In addition, downregulation of PDIA4 promoted apoptosis and inhibited proliferation of GBM. Meanwhile, there was a concurrent decrease in aerobic glycolysis metabolites. Mechanistically, PDIA4 downregulation promoted the apoptosis of GBM cells by increased the expression of apoptosis pathway proteins (caspase 3, caspase 9 and Bax). Downregulation of PDIA4 decreased energy demand and inhibited GBM growth in vitro and in vivo. Besides, such effect also inhibited the PI3K/AKT/m-TOR pathway by inhibiting protein phosphorylation levels of PI3K, AKT and m-TOR. After addition of PI3K/AKT/mTOR pathway activator 740Y-P, the effect of PDIA4 knockdown on GBM was reversed. Therefore, we believe that PDIA4 regulates the proliferation via activating the PI3K/AKT/m-TOR pathway and suppression of apoptosis in glioblastoma. It could be used as a potential target for the treatment of GBM.

UI MeSH Term Description Entries

Related Publications

Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
September 2021, Cancer cell international,
Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
January 2022, Open medicine (Warsaw, Poland),
Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
January 2020, OncoTargets and therapy,
Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
September 2022, Aging,
Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
August 2019, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
January 2020, Drug design, development and therapy,
Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
December 2020, Journal of cellular and molecular medicine,
Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
January 2019, Journal of drug targeting,
Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
January 2022, Open medicine (Warsaw, Poland),
Ming Wang, and Wenyan Zhang, and Yibo Liu, and Zhigang Ma, and Wei Xiang, and Yuqi Wen, and Dingkun Zhang, and Yanling Li, and Yeming Li, and Tao Li, and Ligang Chen, and Jie Zhou
October 2018, Oncology letters,
Copied contents to your clipboard!